Condition
Hemimegalencephaly
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Not Yet Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07287202Phase 1Not Yet Recruiting
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
NCT04344626Not ApplicableWithdrawn
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
Showing all 2 trials